Non-Current Liabilities
Long-Term Debt
Bristol-Myers Squibb Long-Term Debt decreased by 0.0% to $44.47B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 8.6%, from $48.67B to $44.47B. Over 4 years (FY 2020 to FY 2024), Long-Term Debt shows relatively stable performance with a -0.4% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalContext dependent
VolatilityStable
First reportedQ3 2015
Last reportedQ4 2025
How to read this metric
An increase indicates higher financial leverage, which can amplify returns on equity but also increases interest expense and financial risk.
Detailed definition
Loans and financial obligations with a maturity period exceeding one year, typically consisting of corporate bonds and n...
Peer comparison
Capital-intensive firms or those with aggressive share buyback programs often carry higher long-term debt than asset-light competitors.
Metric ID:
long_term_debtHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $42.50B | $39.68B | $39.61B | $37.45B | $37.11B | $36.97B | $35.06B | $35.08B | $34.66B | $32.14B | $36.65B | $49.49B | $48.86B | $48.67B | $47.60B | $46.16B | $44.47B | $44.47B |
| QoQ Change | — | -6.6% | -0.2% | -5.4% | -0.9% | -0.4% | -5.2% | +0.1% | -1.2% | -7.3% | +14.1% | +35.0% | -1.3% | -0.4% | -2.2% | -3.0% | -3.7% | -0.0% |
| YoY Change | — | — | — | — | -12.7% | -6.8% | -11.5% | -6.3% | -6.6% | -13.1% | +4.6% | +41.1% | +41.0% | +51.5% | +29.9% | -6.7% | -9.0% | -8.6% |
Range$32.14B – $49.49B
CAGR+1.1%
Avg YoY Growth+6.2%
Median YoY Growth-6.7%
Current Streak6 quarters decline
Long-Term Debt at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's long-term debt?
- Bristol-Myers Squibb (BMY) reported long-term debt of $44.47B in Q3 2025.
- How has Bristol-Myers Squibb's long-term debt changed year-over-year?
- Bristol-Myers Squibb's long-term debt decreased by 8.6% year-over-year, from $48.67B to $44.47B.
- What is the long-term trend for Bristol-Myers Squibb's long-term debt?
- Over 4 years (2020 to 2024), Bristol-Myers Squibb's long-term debt has grown at a -0.4% compound annual growth rate (CAGR), from $48.34B to $47.60B.
- What does long-term debt mean?
- Money the company has borrowed that doesn't need to be paid back for at least a year.